OverviewChartNewsTraderScreen

Clinuvel Pharmaceuticals Ltd./  US1887691038  /

Nasdaq Other OTC
6/14/2024  4:21:38 PM Chg. -0.4450 Volume Bid- Ask- High Low
9.5550USD -4.45% 100
Turnover: 955.5000		 -Bid Size: - -Ask Size: - 9.5550 9.5550
GlobeNewswire 11/8/2021 CLINUVEL Expands Pharmaceutical Portfolio
GlobeNewswire 3/24/2021 CLINUVEL expands DNA Repair Program
GlobeNewswire 10/27/2020 CLINUVEL to Trial Innovative Drug in Stroke
GlobeNewswire 9/15/2020 First patient dosed in SCENESSE® DNA Repair Program
GlobeNewswire 9/10/2020 CLINUVEL progresses innovative DNA Repair Program
GlobeNewswire 8/31/2020 CLINUVEL Opens VALLAURIX R&D Centre In Singapore
GlobeNewswire 7/13/2020 PRÉNUMBRA® - CLINUVEL's Second Afamelanotide Formulation
GlobeNewswire 4/23/2020 SCENESSE® to be Prescribed in China
GlobeNewswire 4/16/2020 Innovative drug launched for rare, isolating, “light intolerance” disorder
GlobeNewswire 10/9/2019 FDA Approves SCENESSE® For Genetic Disorder
GlobeNewswire 6/3/2019 US FDA Review for SCENESSE® Extended by Three Months
GlobeNewswire 1/10/2019 US FDA sets PDUFA date for SCENESSE®
GlobeNewswire 12/19/2018 Phase II study: SCENESSE® in combination with narrowband ultraviolet B (NB-UVB) achieves repigmentat...
GlobeNewswire 8/29/2018 CLINUVEL delivers second positive financial result
GlobeNewswire 6/25/2018 FDA to Review Australian Drug for Genetic Disorder of Absolute Light Intolerance
GlobeNewswire 2/20/2018 CLINUVEL unveils new global positioning
GlobeNewswire 1/22/2018 Nasdaq Welcomes Cielo S.A. to the Nasdaq International Designation
GlobeNewswire 1/22/2018 Nasdaq Welcomes Cielo S.A. to the Nasdaq International Designation
GlobeNewswire 4/12/2017 CLINUVEL reaches agreement on German SCENESSE® pricing through AMNOG Arbitration Board
GlobeNewswire 6/1/2016 Nasdaq Welcomes Additional Companies to the Nasdaq International Designation